Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

(d) On March 29, 2017, David Carberry and Jim Biehl were each elected to serve on the Company’s board of directors (the “Board”). The Board elected Mr. Carberry and Mr. Biehl as additional directors on our Board, in accordance with our Company’s Bylaws.

David Carberry, 64, is a retired healthcare financial executive with over 40 years of experience in the industry. Most recently, from April 2012 to June 2016 Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. Prior to that, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company, for three years. Mr. Carberry also served in a number of financial oversight roles within Johnson & Johnson and related divisions between 1981 and 2008, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, a joint venture, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider.

Jim Biehl, 53, has been a partner at the law firm of Drinker Biddle & Reath LLP in Princeton, NJ since 1989 in the Corporate and Securities group. As a corporate lawyer with over 25 years of experience representing public and private companies with structuring, negotiating and managing sophisticated securities and corporate transactional matters, he has extensive experience with federal and state securities laws, public debt and equity financings, mergers and acquisitions, corporate venture transactions, joint ventures and strategic alliances, emerging company formation and management, and corporate governance matters. Jim’s industry experience includes representing big pharma, healthcare systems, healthcare consulting firms, consumer products, and medical device companies.

There is no arrangement or understanding between Mr. Carberry or Mr. Biehl and any other persons to which either was selected as a director. There are no family relationships between Mr. Carberry or Mr. Biehl and any director or executive officer of the Company and no transactions involving Mr. Carberry that would require disclosure under Item 404(a) of Regulation S-K. Mr. Biehl’s law firm, Drinker Biddle & Reath LLP, provides legal counsel services to the Company.

Effective March 29, 2017, Mr. Carberry and Mr. Biehl will each be entitled to receive non-employee director compensation as approved by us and in effect from time to time. Our current non-employee director compensation program that is in effect is described in a separate Form 8-K filed as of May 13, 2016, and such terms are incorporated herein by reference.

– 2 –

About Tyme Technologies, Inc. (OTCMKTS:TYMI)

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.

Tyme Technologies, Inc. (OTCMKTS:TYMI) Recent Trading Information

Tyme Technologies, Inc. (OTCMKTS:TYMI) closed its last trading session up +0.01 at 3.02 with 110 shares trading hands.